01/25/2021: Kardium announces $115M in new financing for innovative atrial fibrillation treatment

Fidelity Management & Research Company LLC and T. Rowe Price funds lead private financing round, which will accelerate commercial growth across Europe and enable a a clinical study for US Food and Drug Administration (FDA) approval.

11/11/2020: Kardium performs first cases with the Globe^® Positioning System

Kardium performs first cases with the Globe® Positioning System

09/08/2020: Kardium Marks First Commercial Procedures of Globe^® Mapping and Ablation System

Prof. Hans Kottkamp of Sana Hospital Benrath and Prof. Philipp Sommer of the Herz- und Diabeteszentrum NRW performed the first procedures with the Globe System.

01/25/2021: B.C. heart device firm Kardium founded by Creo executives raises $115-million from Fidelity, T. Rowe Price ahead of going public

Kardium's Globe Mapping and Ablation System is intended to disrupt a roughly $6-billion market for treating atrial fibrillation, which is expected to grow by 15 per cent a year as Baby Boomers age.

09/30/2020: B.C. companies seeking new markets take advantage of favourable travel policies (BIV)

The EU’s favourable polic, is creating advantages for Canadian firms like Kardium looking to expand globally amid the pandemic.

09/11/2020: Kardium completes first commercial procedures with the Globe Mapping and Ablation System

Early successes in roll-out of world’s most complete solution for atrial fibrillation